Pharma’s big bet on cell and gene therapy
In the ever-evolving landscape of biotechnology and pharmaceuticals, one sector has emerged as particularly promising in the quest to combat previously untreatable diseases: cell and gene therapy. Half a century after scientists proposed the idea of modifying defective genes to treat diseases with a genetic root, the approach is beginning to bear fruit.
Biopharma Dealmakers—a Nature publication—reports that, to date, the FDA has approved 31 cell and gene therapies, ten of which are targeting oncology indications. While these ground-breaking cell and gene therapy technologies have the potential to revolutionize medicine, the journey from laboratory to market is fraught with complexity, and subsequently, effective dealmaking remains crucial. Biopharma Dealmakers reveals that 2023 saw 246 partnership deals focused on cell and gene therapy programs—with the top transactions reaching a potential value of $16.8 billion.
For details on the deals that took place, view the full article on Biopharma Dealmakers.
To reach and collaborate with potential partners and investors for your cell and gene therapies, get in touch about advertising with Biopharma Dealmakers.
About Biopharma Dealmakers
Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles.
The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.
